Traders Circulate ‘Struggling Editas Shops Preclinical Cancer Pipeline During Its Big Makeover’ – Endpoints News

EXCLUSIVE: Struggling Editas shops preclinical cancer pipeline during its big makeover – Endpoints News (endpts.com)

byBenzinga Newsdesk

October 18, 2022

1 minute read

EXCLUSIVE: Struggling Editas shops preclinical cancer pipeline during its big makeover – Endpoints News (endpts.com)

Olin Corp Director Sold 3 Million Shares Worth $150 Million In Company Stock

By Benzinga Insights

Today, 4:56 AM

Scott Ferguson, at Olin (NYSE:OLN), made a large insider sell on September 1, according to a new SEC filing.

OLN

Bank Analyst: Yield Curve Inversion ‘Hard To Ignore’, Plus Top Bank Stock Ideas

By Wayne Duggan

Today, 4:56 AM

On Thursday, the yield curve between 2-year and 10-year U.S. Treasury bonds inverted for the first time since 2019, an economic recession indicator that has been extremely reliable over the past century.

EWBC

Citigroup Maintains Buy on Remitly Global, Lowers Price Target to $19

By Benzinga Newsdesk

Today, 4:56 AM

Citigroup analyst Andrew Schmidt maintains Remitly Global (NASDAQ:RELY) with a Buy and lowers the price target from $21 to $19.

RELY

Legal
News

Align Tech Reports Settlement Of Outstanding Litigation With 3Shape, No Terms Disclosed

By Benzinga Newsdesk

Today, 4:56 AM

Align Technology, Inc. (NASDAQ:ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad CAD/CAM software for

ALGN

Traders Circulate ‘Struggling Editas Shops Preclinical Cancer Pipeline During Its Big Makeover’ – Endpoints News

Related Posts

Olin Corp Director Sold 3 Million Shares Worth $150 Million In Company Stock

Bank Analyst: Yield Curve Inversion ‘Hard To Ignore’, Plus Top Bank Stock Ideas

Citigroup Maintains Buy on Remitly Global, Lowers Price Target to $19

Align Tech Reports Settlement Of Outstanding Litigation With 3Shape, No Terms Disclosed